See more : KINS Technology Group Inc. (KINZ) Income Statement Analysis – Financial Results
Complete financial analysis of Twist Bioscience Corporation (TWST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Twist Bioscience Corporation, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Talkweb Information System Co.,Ltd. (002261.SZ) Income Statement Analysis – Financial Results
- Melkior Resources Inc. (MKRIF) Income Statement Analysis – Financial Results
- Sajodaerim Corporation (003960.KS) Income Statement Analysis – Financial Results
- Karsten S.A. (CTKA3.SA) Income Statement Analysis – Financial Results
- Hextar Global Berhad (5151.KL) Income Statement Analysis – Financial Results
Twist Bioscience Corporation (TWST)
Industry: Medical - Diagnostics & Research
Sector: Healthcare
Website: https://www.twistbioscience.com
About Twist Bioscience Corporation
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 312.97M | 245.11M | 203.57M | 132.33M | 90.10M | 54.39M | 25.43M | 10.77M | 2.27M |
| Cost of Revenue | 179.63M | 155.38M | 119.33M | 80.62M | 61.41M | 47.43M | 32.19M | 24.02M | 9.42M |
| Gross Profit | 133.35M | 89.73M | 84.24M | 51.71M | 28.69M | 6.96M | -6.76M | -13.25M | -7.15M |
| Gross Profit Ratio | 42.61% | 36.61% | 41.38% | 39.08% | 31.85% | 12.80% | -26.59% | -123.09% | -315.20% |
| Research & Development | 90.85M | 106.89M | 120.31M | 69.07M | 43.01M | 35.68M | 20.35M | 19.17M | 18.23M |
| General & Administrative | 0.00 | 186.84M | 210.55M | 133.40M | 102.07M | 78.83M | 42.55M | 25.96M | 18.07M |
| Selling & Marketing | 0.00 | 2.90M | 2.40M | 2.50M | 1.20M | 1.30M | 900.00K | 100.00K | 200.00K |
| SG&A | 218.40M | 189.74M | 212.95M | 135.90M | 103.27M | 80.13M | 43.45M | 26.06M | 18.27M |
| Other Expenses | 44.93M | 10.26M | -1.09M | -1.37M | -182.00K | -265.00K | -121.00K | -55.00K | 73.00K |
| Operating Expenses | 354.18M | 306.89M | 333.26M | 204.97M | 146.27M | 115.81M | 63.80M | 45.23M | 36.50M |
| Cost & Expenses | 533.81M | 462.27M | 452.59M | 285.59M | 207.68M | 163.24M | 95.99M | 69.25M | 45.93M |
| Interest Income | 15.34M | 14.37M | 3.06M | 435.00K | 1.50M | 3.03M | 999.00K | 412.00K | 241.00K |
| Interest Expense | 29.00K | 5.00K | 80.00K | 367.00K | 787.00K | 1.29M | 1.31M | 905.00K | 746.00K |
| Depreciation & Amortization | 31.43M | 29.31M | 36.64M | 11.99M | 6.68M | 6.31M | 5.73M | 5.02M | 4.23M |
| EBITDA | -176.71M | -174.15M | -191.55M | -143.91M | -132.09M | -99.77M | -63.95M | -53.10M | -39.11M |
| EBITDA Ratio | -56.46% | -71.05% | -121.36% | -116.52% | -129.04% | -195.06% | -251.52% | -493.21% | -1,723.80% |
| Operating Income | -220.83M | -217.16M | -249.02M | -153.26M | -117.58M | -108.85M | -70.56M | -58.48M | -43.66M |
| Operating Income Ratio | -70.56% | -88.60% | -122.33% | -115.81% | -130.50% | -200.15% | -277.50% | -543.16% | -1,924.02% |
| Total Other Income/Expenses | 12.67M | 13.69M | 6.50M | -1.30M | 530.00K | 1.47M | -435.00K | -548.00K | -432.00K |
| Income Before Tax | -208.17M | -203.47M | -228.27M | -154.03M | -139.55M | -107.38M | -70.99M | -59.03M | -44.09M |
| Income Before Tax Ratio | -66.51% | -83.01% | -112.14% | -116.39% | -154.88% | -197.44% | -279.21% | -548.25% | -1,943.06% |
| Income Tax Expense | 560.00K | 1.15M | -10.41M | -1.93M | 382.00K | 292.00K | 242.00K | 280.00K | 819.00K |
| Net Income | -208.73M | -204.62M | -217.86M | -152.10M | -139.93M | -107.67M | -71.24M | -59.31M | -44.09M |
| Net Income Ratio | -66.69% | -83.48% | -107.02% | -114.94% | -155.31% | -197.98% | -280.16% | -550.85% | -1,943.06% |
| EPS | -3.60 | -3.60 | -4.04 | -3.15 | -3.57 | -3.92 | -2.68 | -3.16 | -2.35 |
| EPS Diluted | -3.60 | -3.60 | -4.04 | -3.15 | -3.57 | -3.92 | -2.68 | -3.16 | -2.35 |
| Weighted Avg Shares Out | 58.02M | 56.89M | 53.89M | 48.25M | 39.19M | 27.46M | 26.61M | 18.78M | 18.78M |
| Weighted Avg Shares Out (Dil) | 58.02M | 56.89M | 53.89M | 48.25M | 39.19M | 27.46M | 26.61M | 18.78M | 18.78M |
2 Cathie Wood Growth Stocks That Could Make You Richer
Cathie Wood's Ark Innovation ETF has been blazing the comeback trail in 2023. Among the fund's various holdings, Twist Biosciences and Exact Sciences stand out as top growth plays right now.
Twist Bioscience and Cancer Research Horizons Enter into Collaboration to Advance Cancer Research
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Cancer Research Horizons, the innovation engine at the core of one of the...
Twist Bioscience DNA-Based Tools Now Available in Ireland From MyBio
KILKENNY, Ireland & SAN FRANCISCO--(BUSINESS WIRE)--MyBio, the life science solutions provider, KILKENNY, Ireland, announces an exclusive distribution agreement with Twist Bioscience, SAN FRANCISCO, United States, bringing its synthetic DNA and next-generation sequencing products to the Irish market. This partnership enables...
Twist Bioscience Publishes Preclinical Data in Diabetes Validating GLP-1R Antagonist Antibody as Potential Treatment for Congenital Hyperinsulinism
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced publication of preclinical data supporting the potential use of the highly potent...
Twist Bioscience Appoints Chet Gandhi as Chief Information Officer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Chet Gandhi as chief information officer. Mr. Gandhi brings...
Twist Bioscience and CeGaT Launch RNA Fusion Panel to Advance Oncology and Precision Medicine Research
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and CeGaT GmbH, a global provider of sequencing services for research, clinical studies, and...
Twist Bioscience to Present at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and...
Twist Bioscience Appoints Robert Werner as Chief Accounting Officer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Robert Werner as chief accounting officer. “Rob has a...
Twist Bioscience Appoints Robert Werner as Chief Accounting Officer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Robert Werner as chief accounting officer. “Rob has a...
Twist Bioscience Launches Portfolio of RNA Sequencing Tools
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of a portfolio of RNA sequencing tools, which includes the...
Source: https://incomestatements.info
Category: Stock Reports